Study | Treatment arms | No. patients (N) | Timepoint (weeks) | Outcomes included in NMA |
ASTRAEA24 | Placebo | 211 | 16 | ACR–20, 50, 70; PASI 75*; EnthR*; DactR*; DAE |
Abatacept 125 mg | 213 | |||
ADEPT70 | Placebo | 162 | 12 | ACR–20, 50, 70; PASI–75, 90; DAE |
Adalimumab 40 mg | 153 | |||
Genovese 200771 | Placebo | 51 | 12 | ACR–20, 50, 70; DAE |
Adalimumab 40 mg | 51 | |||
Mease 201861 | Placebo | 24 | 12 | ACR–20, 50, 70; PASI–75; 90; DAE |
Adalimumab 40 mg | 72 | |||
Remtolumab 120 mg | 71 | |||
Remtolumab 240 mg | 73 | |||
ACTIVE62 | Placebo | 109 | 16 | ACR–20, 50, 70; DAE |
Apremilast 30 mg twice daily | 110 | |||
Schett 201236 | Placebo | 68 | 12 | ACR–20, 50, 70; DAE |
Apremilast 20 mg twice daily | 69 | |||
Apremilast 40 mg once daily | 67 | |||
PALACE 137 | Placebo | 168 | 16 | ACR–20, 50, 70; PASI 75*; EnthR; DactR; DAE |
Apremilast 20 mg twice daily | 168 | |||
Apremilast 30 mg twice daily | 168 | |||
PALACE 238 | Placebo | 159 | 16 | ACR–20, 50, 70; PASI 75; EnthR; DactR; DAE |
Apremilast 20 mg twice daily | 163 | |||
Apremilast 30 mg twice daily | 162 | |||
PALACE 339 | Placebo | 169 | 16 | ACR–20, 50, 70; PASI 75; EnthR; DactR; DAE |
Apremilast 20 mg twice daily | 169 | |||
Apremilast 30 mg twice daily | 167 | |||
Mease 201422 | Placebo | 55 | 12 | ACR–20, 50, 70; DAE |
Brodalumab 140 mg | 57 | |||
Brodalumab 280 mg | 56 | |||
AMVISION 123 | Placebo | 161 | 16 | ACR–20, 50, 70; PASI–75, 90; EnthR; DactR; DAE |
Brodalumab 140 mg | 158 | |||
Brodalumab 210 mg | 159 | |||
AMVISION 223 | Placebo | 161 | 16 | ACR–20, 50, 70; PASI–75, 90; EnthR; DactR; DAE |
Brodalumab 140 mg | 160 | |||
Brodalumab 210 mg | 163 | |||
RAPID-PsA40 | Placebo | 136 | 12 | ACR–20, 50, 70; PASI–75, 90; DAE |
Certolizumab 200 mg every two weeks | 138 | |||
Certolizumab 400 mg every four weeks | 135 | |||
Mease 200472 | Placebo | 104 | 12 | ACR–20, 50, 70; PASI 75*; DAE |
Etanercept 25 mg twice weekly | 101 | |||
PRESTA63 | Etanercept 50 mg once weekly | 373 | 12 | ACR–20, 50, 70; PASI 75*; DAE |
Etanercept 50 mg twice weekly | 379 | |||
SEAM-PsA66 | Placebo +MTX 20 mg once weekly | 284 | 16 | ACR–20, 50, 70; DAE |
Placebo +Etanercept 50 mg once weekly | 284 | |||
Etanercept 50 mg +MTX 20 mg once weekly | 283 | |||
EQUATOR26 | Placebo | 66 | 16 | ACR–20, 50, 70; PASI 75; EnthR; DactR; DAE |
Filgotinib 200 mg | 65 | |||
GO-REVEAL41 | Placebo | 113 | 14 | ACR–20, 50, 70; PASI–75, 90; DAE |
Golimumab 50 mg | 146 | |||
Golimumab 100 mg | 146 | |||
GO-VIBRANT42 | Placebo | 239 | 14 | ACR–20, 50, 70; PASI–75, 90; DAE |
Golimumab 2 mg/kg | 241 | |||
GO-DACT64 | Placebo +MTX 15–25 mg | 23 | 12 | DactR |
Golimumab 50 mg +MTX 15–25 mg | 21 | |||
DISCOVER 117 | Placebo | 126 | 16 | ACR–20, 50, 70; PASI*–75, 90; EnthR*, DactR*; DAE |
Guselkumab 100 mg every eight weeks | 128 | |||
Guselkumab 100 mg every four weeks | 128 | |||
DISCOVER 218 | Placebo | 247 | 16 | ACR–20, 50, 70; PASI*–75, 90; EnthR*; DactR*; DAE |
Guselkumab 100 mg every eight weeks | 248 | |||
Guselkumab 100 mg every four weeks | 246 | |||
Deodhar 201819 | Placebo | 49 | 16 | ACR–20, 50, 70; PASI*–75, 90; EnthR*; DactR*; DAE |
Guselkumab 100 mg every eight weeks | 100 | |||
IMPACT43 | Placebo | 52 | 16 | ACR–20, 50, 70; PASI–75, 90; DAE |
Infliximab 5 mg/kg | 52 | |||
IMPACT 244 | Placebo | 100 | 14 | ACR–20, 50, 70; PASI–75, 90; DAE |
Infliximab 5 mg/kg | 100 | |||
RESPOND65 | Infliximab 5 mg/kg+MTX 15 mg | 57 | 16 | ACR–20, 50, 70; PASI–75, 90; DAE |
MTX 15 mg | 58 | |||
SPIRIT H2H45 | Adalimumab 40 mg | 283 | 16 | ACR–50; PASI*–75, 90; EnthR*; DactR*; DAE |
Ixekizumab 80 mg | 283 | |||
SPIRIT P146 | Placebo | 106 | 12 | ACR–20, 50, 70; PASI–75, 90; EnthR†; DactR†; DAE |
Adalimumab 40 mg | 101 | |||
Ixekizumab 80 mg every four weeks | 107 | |||
Ixekizumab 80 mg every two weeks | 103 | |||
SPIRIT P247 | Placebo | 118 | 12 | ACR†–20, 50, 70; PASI–75, 90; EnthR; DactR; DAE |
Ixekizumab 80 mg every four weeks | 122 | |||
Ixekizumab 80 mg every two weeks | 123 | |||
PATERA48 | Placebo | 97 | 24 | ACR–20, 50, 70 |
Netakimab 120 mg | 97 | |||
CHOICE49 | Placebo | 52 | 16 | ACR–20, 50, 70; PASI–75, 90; EnthR; DactR; DAE |
Secukinumab 150 mg | 103 | |||
Secukinumab 300 mg | 103 | |||
FUTURE 150 | Placebo | 202 | 16 | ACR–20, 50, 70; PASI*–75, 90; EnthR*; DactR*; DAE |
Secukinumab 75 mg (IV LD) | 202 | |||
Secukinumab 150 mg (IV LD) | 202 | |||
FUTURE 251 | Placebo | 98 | 16 | ACR–20, 50, 70; PASI*–75, 90; EnthR*; DactR*; DAE |
Secukinumab 75 mg (SC LD) | 99 | |||
Secukinumab 150 mg | 100 | |||
Secukinumab 300 mg | 100 | |||
FUTURE 367 | Placebo | 137 | 16 | ACR–20, 50; PASI*–75, 90; EnthR*; DactR*; DAE |
Secukinumab 150 mg | 138 | |||
Secukinumab 300 mg | 139 | |||
FUTURE 468 | Placebo | 114 | 16 | ACR–20, 50, 70; PASI–75, 90; EnthR; DactR |
Secukinumab 150 mg (no LD) | 113 | |||
Secukinumab 150 mg | 114 | |||
FUTURE 552 | Placebo | 332 | 16 | ACR–20, 50, 70; PASI–75, 90; EnthR; DactR; DAE |
Secukinumab 150 mg (no LD) | 222 | |||
Secukinumab 150 mg | 220 | |||
Secukinumab 300 mg | 222 | |||
EXCEED53 | Adalimumab 40 mg | 427 | 16 | ACR–20, 50, 70; PASI–75, 90; EnthR; DactR; DAE |
Secukinumab 300 mg | 426 | |||
MAXIMISE69 | Placebo | 166 | 12 | ACR 20 |
Secukinumab 150 mg | 165 | |||
Secukinumab 300 mg | 167 | |||
Gottlieb 201920 | Placebo | 79 | 16 | ACR–20, 50, 70; PASI–75, 90; DAE |
Tildrakizumab 20 mg | 78 | |||
Tildrakizumab 100 mg | 77 | |||
Tildrakizumab 200 mg | 79 | |||
Opal Beyond54 | Placebo | 131 | 13 | ACR–20, 50, 70; PASI 75; EnthR; DactR; DAE |
Tofacitinib 5 mg twice daily | 131 | |||
Tofacitinib 10 mg twice daily | 132 | |||
Opal Broaden55 | Placebo | 105 | 13 | ACR–20, 50, 70; PASI 75; EnthR; DactR; DAE |
Adalimumab 40 mg | 106 | |||
Tofacitinib 5 mg twice daily | 107 | |||
Tofacitinib 10 mg twice daily | 104 | |||
SELECT-PsA 156 | Placebo | 423 | 16 | ACR‡–20, 50, 70; PASI 75; EnthR1; DactR1; DAE |
Upadacitinib 15 mg once daily | 429 | |||
Upadacitinib 30 mg once daily | 423 | |||
Adalimumab 40 mg | 429 | |||
SELECT-PsA 257 | Placebo | 212 | 16 | ACR‡–20, 50, 70; PASI 75; EnthR; DactR; DAE |
Upadacitinib 15 mg once daily | 211 | |||
Upadacitinib 30 mg once daily | 218 | |||
Gottlieb 200958 | Placebo | 70 | 12 | ACR–20, 50, 70; PASI–75, 90; DAE |
Ustekinumab 90 mg | 76 | |||
PSUMMIT 159 | Placebo | 206 | 16 | ACR–20; PASI 75*; EnthR*; DactR*; DAE |
Ustekinumab 45 mg | 205 | |||
Ustekinumab 90 mg | 204 | |||
PSUMMIT 260 | Placebo | 104 | 16 | ACR–20; PASI 75*; EnthR*; DactR*; DAE |
Ustekinumab 45 mg | 103 | |||
Ustekinumab 90 mg | 105 |
*Data reported at week 24.
†Data reported at week 16.
‡Data reported at week 12.
ACR, American College of Rheumatology; DactR, resolution of dactylitis; DAE, withdrawal due to adverse events; EnthR, resolution of enthesitis; IV, intravenous; LD, loading dose; MTX, methotrexate; NMA, network meta-analysis; PASI, Psoriasis Area and Severity Index; SC, subcutaneous.